REVIEW  STEMI: CURRENT KNOWLEDGE AND FUTURE PERSPECTIVES 

Minerva Cardioangiologica 2018 August;66(4):422-8

DOI: 10.23736/S0026-4725.18.04640-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Antiplatelet therapy in STEMI undergoing primary PCI: when, which one and how long

Giorgio BARALIS, Roberta ROSSINI, Giuseppe MUSUMECI ✉

Unit of Cardiology, Department of Emergencies and Critical Areas, Santa Croce e Carle Hospital, Cuneo, Italy

Reperfusion therapy for patients presenting with an acute ST-segment elevation myocardial infarction (STEMI) involves primary percutaneous coronary intervention (PPCI) and concomitant dual antiplatelet therapy (DAPT) with combination of a P2Y12 inhibitor and acetylsalicylic acid (ASA). Decision regarding DAPT can be challenging clinically in the modern era with the evolution of newer stents, more potent antiplatelet agents and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. This review outlines the currently available antiplatelet treatments, and their place within the therapeutic timeline of a patient presenting with STEMI.

KEY WORDS: Aspirin - Stents - Anticoagulants